disease mediated by aberrant immune responses 1, 2, 8 . Therefore, targeting the dysregulated immunological pathways that underlie EoE could offer new treatment strategies for this disease. Studies investigating the immunological mechanisms that mediate EoE have shown that various immune cell types, including eosinophils, mast cells, type 2 helper T (T H 2) cells that produce interleukin-4 (IL-4), IL-5, and IL-13, and IgE-producing B cells, may contribute to esophageal inflammation during EoE [1] [2] [3] 9 . Further, recent work has shown that there is a strong association between a gain-of-function polymorphism in the gene that encodes the predominantly epithelial cell-derived cytokine TSLP and the development of EoE in children 10, 11 . TSLP is associated with multiple allergic disorders [10] [11] [12] [13] [14] [15] [16] and is thought to promote allergic inflammation by activating dendritic cells, inducing T H 2 cell responses, supporting IgE production and eliciting the population expansion of phenotypically and functionally distinct basophils 12, [17] [18] [19] [20] [21] . However, whether TSLP directly promotes inflammatory responses associated with EoE and the mechanisms by which polymorphisms in TSLP and increased TSLP expression may contribute to the pathogenesis of EoE in patients has been unknown.
RESULTS

A new mouse model of experimental EoE-like disease
To investigate whether TSLP directly promotes EoE disease pathogenesis, we developed a new mouse model of EoE-like disease that is associated with exaggerated TSLP production. Multiple studies in mouse models and humans suggest that sensitization to food allergens may occur at sites where the skin barrier is disrupted, such as atopic dermatitis lesions [22] [23] [24] . Thus, we employed a model in which mice were epicutaneously sensitized to a food antigen, ovalbumin (OVA), on a developing atopic dermatitis-like skin lesion induced by topical treatment with the vitamin D analog MC903 (Fig. 1a) . Consistent with previous reports 17, [25] [26] [27] , wild-type (WT) BALB/c mice treated epicutaneously with the vitamin D analog MC903 showed increased TSLP expression in the skin compared to ethanol vehicle-treated control mice (Fig. 1b) . Epicutaneous sensitization to and subsequent oral challenge with OVA resulted in the development of experimental EoElike disease that was characterized by inflammation, edema and eosinophilia in the esophagus, as measured histologically and quantified by enumeration of eosinophils per high-power field (HPF) (Fig. 1c,d ). Flow cytometric analysis (Fig. 1e,f) and immunofluorescence staining (Fig. 1g ) also demonstrated that there was an accumulation of eosinophils in esophageal tissues of mice with EoE-like disease, and electron microscopic (EM) analysis revealed the presence of degranulated eosinophils in these tissues (Fig. 1h) . We also observed significantly higher expression of genes that encode T H 2 cytokines and the basophil-specific protease Mcpt8 and a trend toward increased Tslp expression in esophageal tissues of mice with EoE-like disease compared to control mice (Fig. 1i) . Further, we observed a similar , showing loss of electron density in granule cores (red arrow), granule extrusion channels (blue arrow) and complete loss of granule contents (green arrow) into the extracellular matrix (purple arrow). Scale bar, 2 µm. (i) mRNA expression of T H 2 cytokines (Il4, Il5, Il13), the basophil-specific protease Mcpt8 and Tslp in the esophagus. Data depicted are from one experiment (EtOH + OVA, n = 3; MC903, n = 3; MC903 + OVA, n = 4) and are representative of three independent replicates. y axis shows fold induction compared to controls (see Online Methods). (j) Representative images of esophagi, with incidence of impaction. Arrowheads identify impacted food. Data depicted are from two pooled experiments (EtOH + OVA, n = 7, MC903 + OVA, n = 9). All parameters were assessed 12 h post-final oral antigen challenge. Data in a-i are from mice challenged twice with OVA, and data in j are from mice challenged six times with OVA. Results are shown as mean ± s.e.m., and a nonparametric, one-way Kruskal-Wallis analysis of variance (ANOVA) with Dunn's post hoc testing was used to determine significance. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. pattern of EoE-like disease in mice that were epicutaneously sensitized to crude peanut extract (CPE) on an atopic dermatitis-like skin lesion ( Supplementary Fig. 1a-c) , confirming that sensitization to a natural food allergen in the presence of elevated amounts of TSLP results in experimental EoE-like disease. Eosinophil accumulation in this model was not restricted to the esophagus, as mice with EoE-like disease also showed eosinophilia in the gastrointestinal tract after epicutaneous sensitization and oral challenge with OVA ( Supplementary  Fig. 1d ,e) associated with antigen-specific T H 2 cytokine responses in the mesenteric lymph node and spleen ( Supplementary Fig. 1f,g ). EoE in humans is diagnosed on the basis of immunological parameters and the presence of physiological changes in esophageal tissue and signs of esophageal dysfunction, including food impaction, which occurs in approximately 40% of patients with EoE [1] [2] [3] 28 . To assess whether clinical manifestations of EoE were present in the experimental mouse model of EoE-like disease, we challenged mice that had existing EoE-like disease repeatedly with OVA to induce prolonged esophageal inflammation. Although analysis using optical coherence tomography (OCT), which allows for high-resolution imaging of live biological tissues based on optical scattering 29, 30 , revealed that EoE-like disease was characterized by minimal changes in the thickness of the esophageal epithelium, (Supplementary Fig. 2a,b) , prolonged esophageal inflammation was associated with food impaction in the esophagus. Approximately 30% of fasted mice with EoE-like disease exhibited food impaction at the time of killing, but we never observed food impaction in the esophagus of control (ethanol)-treated mice (Fig. 1j) . Collectively, these data indicate that this new model of EoE-like disease is characterized by a number of immunological and pathophysiological changes in esophageal tissues and signs of esophageal dysfunction similar to those observed in humans with EoE 1-3,31-34 .
EoE-like disease is dependent on TSLP but independent of IgE To determine whether TSLP directly promotes the pathogenesis of experimental EoE-like disease in mice, we epicutaneously sensitized WT BALB/c (Tslpr +/+ ) mice or mice deficient in the TSLP receptor (TSLPR) (Tslpr −/− ) to OVA followed by oral antigen challenge (see Fig. 1a ). Whereas sensitized and challenged Tslpr +/+ mice showed esophageal eosinophilia and associated inflammation, Tslpr −/− mice did not develop esophageal eosinophilia (Fig. 2a-d) . Using an alternative approach to abrogate TSLP signaling, we found that multiple systemic treatments with a monoclonal antibody (mAb) that neutralizes TSLP during epicutaneous sensitization with OVA in WT BALB/c mice also limited eosinophil infiltration in the esophagus after oral challenge ( Fig. 2e-h) .
To test whether TSLP was sufficient for the development of EoE-like disease during epicutaneous sensitization, we intradermally injected mice with exogenous recombinant TSLP (rTSLP) in the presence or absence of OVA and challenged them orally (Supplementary Fig. 3a) . Mice sensitized to OVA in the presence of rTSLP also showed esophageal eosinophilia after oral challenge compared to mice treated with OVA alone or rTSLP alone (Supplementary Fig. 3b) . In a complementary approach, Tslpr +/+ mice were treated with control antibody or a TSLP-specific mAb, and Tslpr −/− mice were sensitized with OVA on tape-stripped skin (Supplementary Fig. 3c ). Tape-stripping was associated with elevated local TSLP production following physical Whereas Tslpr +/+ mice treated with control antibody that were sensitized to OVA on tape-stripped skin showed esophageal eosinophilia after oral antigen challenge, Tslpr +/+ mice treated with a TSLP-specific mAb and Tslpr −/− mice did not develop esophageal eosinophilia ( Supplementary Fig. 3e,f) . Finally, we assessed the contribution of TSLP to the development of clinical signs of EoE-like disease. Repeated challenge with OVA following sensitization in the presence of MC903 was not associated with changes in the thickness of the esophageal epithelium. However, prolonged esophageal inflammation was associated with an increased incidence of food impaction in the esophagus in Tslpr +/+ but not Tslpr −/− mice ( Supplementary  Fig. 4a,b) . Collectively, these data indicate that TSLP-TSLPR interactions are necessary and sufficient for the development of experimental EoE-like disease in mice. TSLP-TSLPR interactions are known to promote the production of IgE 36,37 , a key mediator of allergic inflammation 38 , and class-switched B cells have been observed in the esophagus of patients with EoE 9,39,40 . In addition, MC903-induced TSLP expression was associated with high amounts of systemic OVA-specific IgE (Fig. 3a) , suggesting that TSLP-dependent EoE-like disease in mice might be IgE dependent. To directly test this, we epicutaneously sensitized IgE-sufficient WT BALB/c (Igh-7 +/+ ) mice and IgEdeficient (Igh-7 −/− ) mice to OVA in the presence of MC903. Following oral challenge with antigen, both Igh-7 +/+ and Igh-7 −/− mice showed equivalent EoE-like disease, characterized by esophageal inflammation, elevated tissue eosinophilia ( Fig. 3b-d) , the presence of degranulated eosinophils in the esophagus (Fig. 3e ) and significant increases in gene expression of T H 2 cytokines in esophageal tissues (Fig. 3f ). These data demonstrate that EoE-like disease can occur in an IgE-independent manner and are consistent with recent findings from clinical studies suggesting that treatment with an IgE-specific mAb does not ameliorate EoE in most patients [41] [42] [43] [44] . Together, these data indicate that manipulation of the IgE pathway may not be an effective therapeutic approach for the treatment of EoE.
EoE-like disease depends on basophils
In addition to its role in promoting B cell and IgE responses, TSLP expression is associated with the selective expansion of a distinct population of basophils 17, 18 . These data suggest that basophils may contribute to TSLP-dependent, IgE-independent EoE-like disease in mice. Consistent with this hypothesis, MC903-induced expression of TSLP in the skin was associated with TSLP-dependent, IgE-independent systemic basophil responses (Supplementary Fig. 5a,b) . To assess whether basophils contribute to the development of experimental EoE-like disease, we employed an established genetic approach to deplete basophils in vivo. C57BL/6 mice in which the diphtheria toxin receptor (DTR) is exclusively expressed by basophils (Baso-DTR + mice) 17, 19, 45 and DTR-negative littermate controls (Baso-DTR − mice) were epicutaneously sensitized and orally challenged with OVA while being treated with diphtheria toxin (Fig. 4a) . Consistent with results observed in BALB/c mice (Fig. 1b) , we observed increased local and systemic TSLP production in C57BL/6 Baso-DTR − and Baso-DTR + mice sensitized to OVA in the context of MC903 treatment (data not shown). Notably, whereas Baso-DTR − mice that were epicutaneously sensitized and orally challenged with OVA showed high frequencies of eosinophils in the esophagus, depletion of basophils in Baso-DTR + mice (Supplementary Fig. 5c ) led to a reduction in esophageal eosinophilia ( Fig. 4b-e) and a reduction in expression of genes related to T H 2 cytokine responses ( Supplementary Fig. 6a-c) .
Using an alternative approach, we treated epicutaneously sensitized and orally challenged WT BALB/c mice with a mAb specific for CD200R3 (Ba103) to deplete basophils 46 (Fig. 4f) . Mice in which basophils were depleted during sensitization (Supplementary Fig. 5d ) showed a reduced accumulation of eosinophils in the esophagus compared to control mAbtreated mice after oral challenge with OVA ( Fig. 4g-j) results indicate that basophils are major contributors to the pathogenesis of experimental EoE-like disease in mice and may represent a new therapeutic target to treat this disease in patients.
TSLP or basophils can be targeted to treat EoE-like disease As TSLP and basophils were required during sensitization for the development of EoE-like disease in mice, we next tested whether the TSLP-basophil pathway could be therapeutically targeted to treat established EoE-like disease. First, we sensitized and challenged mice with OVA to establish EoE-like disease and then treated them systemically with either an isotype control or a neutralizing TSLP-specific mAb during repeated antigen challenge (Fig. 5a ). Whereas mice with established EoE-like disease treated with a control antibody showed esophageal eosinophilia, mice that were treated with a TSLP-specific mAb had decreased esophageal eosinophilia, as measured histologically (Fig. 5b) . Flow cytometric analysis also revealed that the total immune cell infiltrate and esophageal eosinophilia were significantly reduced in mice treated with a TSLP-specific mAb compared to mice treated with a control mAb (Fig. 5c,d ).
To test whether basophils contributed to the maintenance of EoElike disease, we treated mice with established EoE-like disease with an isotype control or basophil-depleting CD200R3-specific mAb during repeated OVA challenge (Fig. 5e) . Similar to the results observed after neutralization of TSLP, specific depletion of basophils resulted in decreased esophageal eosinophilia, as measured histologically (Fig. 5f) , and flow cytometric analysis showed a reduction in total immune cell infiltrate and eosinophil numbers in the esophagus (Fig. 5g,h) . To test whether neutralization of TSLP or depletion of basophils was also associated with a resolution of signs of esophageal dysfunction, we treated mice with established EoE-like disease with a control antibody, TSLP-specific mAb, or CD200R3-specific mAb and assessed them for the incidence of food impaction. Whereas we observed food impaction in about 30% of mice treated with a control antibody, we did not observe food impaction in mice in which TSLP or basophil responses were blocked (Fig. 5i) . Taken together, these data demonstrate that TSLP neutralization or basophil depletion can be used to ameliorate inflammation and clinical symptoms of established experimental EoE-like disease in mice.
The TSLP-basophil axis is associated with EoE in humans The roles of TSLP and basophils in experimental EoE-like disease in mice (Figs. 2 and 4) and the established association between a gain-of-function polymorphism in TSLP and EoE in human pediatric subjects 10, 11 prompted us to hypothesize that the TSLP-basophil pathway may contribute to the pathogenesis of EoE in humans. To assess whether the TSLP-basophil axis is active in human subjects with EoE, we examined TSLP expression and basophil responses in esophageal biopsies from a cohort of pediatric subjects. We stratified this patient population on the basis of the number of eosinophils counted in histologic sections from esophageal biopsies into the following groups: (i) control subjects without EoE, (ii) subjects with active EoE (≥15 eosinophils per HPF) and (iii) subjects with inactive EoE (<15 eosinophils per HPF and a prior clinical history of active EoE) (Fig. 6a) . In agreement with previous studies 10 TSLP expression in esophageal biopsies was higher in subjects with active EoE compared to control subjects or subjects with inactive EoE (Fig. 6b) . Immunohistochemical staining revealed that stratified squamous epithelial cells showed positive staining for TSLP in esophageal biopsies from subjects with active EoE (Fig. 6c) . We then used flow cytometric analysis to identify and quantify the inflammatory cell infiltrate in biopsies. Notably, we observed higher frequencies of cells with a phenotype consistent with that of basophils (lin − CD49b + FcεRI + c-kit − 2D7 + ) in esophageal biopsies from subjects with active EoE compared to those from control subjects or subjects with inactive EoE (Fig. 6d,e) . Further, the frequency of basophils positively correlated (Spearman r = 0.6638) with the number of eosinophils counted per HPF in histological sections of esophageal biopsies (Fig. 6f) . Additionally, we were able to stratify a cohort of adult subjects on the basis of the number of eosinophils counted in histologic sections (Supplementary Fig. 7a ). Consistent with results observed in pediatric subjects (Fig. 6d-f ), adult subjects with active EoE had a higher (although not statistically significant) frequency of basophils in the esophageal biopsy, as measured using flow cytometry, that positively correlated (Spearman r = 0.5282) with the number of eosinophils counted per HPF in histological sections ( Supplementary  Fig. 7b,c) . Collectively, these data indicate for the first time, to our knowledge, that the TSLP-basophil axis is associated with active EoE in pediatric and adult subjects. These findings, coupled with the association between the development of EoE and a previously identified gain-of-function polymorphism in TSLP associated with TSLP overexpression (TSLP risk ) 10 , suggested that there may be an association between the TSLP risk polymorphism and enhanced basophil responses in human subjects with EoE. To directly test this, we assessed a separate cohort of pediatric subjects with active or inactive EoE genotyped for the presence of the TSLP risk polymorphism for basophil frequencies among peripheral blood mononuclear cells (PBMCs). Subjects who were homozygous or heterozygous for the TSLP risk polymorphism had significantly higher basophil frequencies in their PBMCs than subjects with EoE who did not carry the TSLP risk polymorphism (Fig. 6g) , which suggests a genetic link between a gain-of-function TSLP polymorphism, increased peripheral basophil responses and EoE. As with most human inflammatory diseases such as asthma, inflammatory bowel disease and multiple sclerosis [47] [48] [49] [50] , the development of EoE probably involves a complex interplay of genetic and environmental factors. However, these data suggest a model in which patients that carry the TSLP risk polymorphism have a predisposition toward TSLP overexpression and associated peripheral basophilia that may increase the likelihood of developing EoE after encounter with trigger antigens (Supplementary Fig. 8 ).
DISCUSSION
Here we describe a new mouse model in which epicutaneous sensitization to a model food antigen followed by oral antigen challenge results in EoE-like disease. We demonstrate that TSLP and basophils, but not IgE, are required for the development of experimental EoE-like disease in mice and that antibody-mediated neutralization of TSLP or depletion of basophils is effective in preventing the development of experimental EoE-like disease. Targeting TSLP or basophils was also effective in treating established EoE-like disease in mice. In addition, we identify for the first time the presence of enhanced basophil responses in the esophageal biopsy tissue of human subjects with EoE and a genetic link between a gain-of-function polymorphism in TSLP and increased peripheral basophil responses. Although all experimental model systems have limitations and do not recapitulate the diversity of symptoms reported in humans, the model of EoE-like disease we report here is associated with several characteristics of EoE in humans, including esophageal eosinophilia and associated esophageal dysfunction. In addition, this model is also characterized by gastrointestinal eosinophilia and systemic T H 2 cytokine responses. EoE in humans is defined as a disease associated with eosinophilia in the esophagus. However, patients with EoE often suffer from coexisting allergic disorders such as atopic dermatitis, allergic rhinitis, asthma or intestinal food allergy 2, 7, 51 . These observations suggest that a subset of individuals with EoE with coexisting allergic diseases may present with manifestations of allergic disease at tissue sites outside of the esophagus 52 . Thus, the mouse model of EoE-like disease we describe may recapitulate a pan-allergic disease state present in some humans who have EoE and suffer from additional allergic diseases. Although EoE-like disease in this model develops independently of IgE and is dependent on TSLP and basophils, further studies will be required to investigate whether the gastrointestinal eosinophilia in this model is dependent on IgE or TSLP-elicited basophils.
Previous studies in mouse models and humans have identified various immunological factors that are associated with EoE 1-3,31-34,53-58 . However, recent clinical trials that have targeted some of these factors, including IgE and IL-5, have failed to ameliorate symptoms of disease 2, 41, 42, 44, 59, 60 , suggesting that these factors may not be essential for the pathogenesis of EoE. The demonstration that EoElike disease in mice can develop independently of IgE but is dependent on TSLP and basophils may explain why previous clinical trials employing other candidate biologic therapies have not been successful. The identification of a role for TSLP and basophils in experimental EoE-like disease in mice, coupled with the association between TSLP and basophil responses and EoE in humans, indicate 
METHODS
Methods and any associated references are available in the online version of the paper. To assess food impaction in the esophagus, mice exposed to prolonged esophageal inflammation were fasted for at least 30 min and up to 2 h. Mice were then killed, and their esophagi were examined for the presence of impacted food.
ONLINE METHODS
Cohort of human subjects with eosinophilic esophagitis. Pediatric participants from a cohort of control subjects or subjects with EoE at the University of Pennsylvania Penn-Children's Hospital of Philadelphia (CHOP) Joint Center for Digestive, Liver and Pancreatic Medicine or the Center for Pediatric Eosinophilic Disorders at CHOP were analyzed and were provided under a CHOP IRB to M.-L.W. and A.J.B. Adult participants from a cohort of control subjects or subjects with EoE being treated at the Hospital of the University of Pennsylvania Division of Gastroenterology were also assessed and were provided under a University of Pennsylvania IRB to G.W.F. and P.M.-K. Written consent was obtained from all participants or their parents or legal guardians, and for pediatric participants, verbal assent from the child was additionally obtained. Subjects defined as having EoE had no other chronic condition except asthma, allergic rhinitis, food allergy, urticaria or atopic dermatitis. Control subjects presented with epigastric abdominal pain but had normal endoscopic and microscopic results. Pediatric subjects with EoE were on proton pump inhibitor therapy, but subjects on systemic corticosteroid treatment or antibiotics were excluded. Subjects with active EoE had an esophageal eosinophil count of ≥15 per HPF after 8 weeks of treatment with a proton pump inhibitor. Subjects with inactive EoE had previously been diagnosed with active EoE but had an esophageal eosinophil count of < 15 per HPF at the time of sample collection. During routine endoscopy, three esophageal biopsies were collected for histological analysis of esophageal eosinophil counts. During the same procedure, two esophageal tissue biopsies were collected for research purposes, for either real-time PCR, immunohistochemistry or flow cytometry. For flow cytometry, single-cell suspensions were made by filtering the mechanically disrupted tissue through a 70-µm filter (BD Biosciences) for flow cytometry. Peripheral blood from pediatric subjects from a cohort of control subjects or subjects with active or inactive EoE that were genotyped for a gain-of-function TSLP polymorphism at the University of Pennsylvania Penn-CHOP Joint Center for Digestive, Liver and Pancreatic Medicine or the Center for Pediatric Eosinophilic Disorders at CHOP was analyzed and was provided under a CHOP IRB to J.M.S. and K.R.R. Written consent was obtained from all participants or their parents or legal guardians, and for pediatric participants, verbal assent from the child was additionally obtained. Peripheral blood was collected by venipuncture, and serum was isolated. PBMCs were isolated by Ficoll gradient as previously described 17 , and cells were analyzed by flow cytometry. For genotyping of pediatric subjects with EoE, all samples were genotyped on either the Illumina HumanHap 550 or 610 BeadChips according to the manufacturer's protocols. Data normalization and canonical genotype clustering were carried out using the Illumina Genome Studio package. Samples with call rate <98% were excluded from further analysis.
Human real-time PCR and immunohistochemistry. For real-time PCR analysis of gene expression in human esophageal biopsies, human subject biopsy samples were collected and placed in RNAlater (Ambion). RNA was isolated using the mirVana miRNA Isolation Kit according to the manufacturer's recommendations (Ambion) and reverse transcribed using a high-capacity cDNA reverse transcriptase kit (Applied Biosystems). Quantitative real-time PCR was performed using the Taqman Fast Universal PCR Master Mix kit and preformulated TaqMan Gene Expression Assays for TSLP (Applied Biosystems). Reactions were performed in triplicate using 96-well optical plates on a StepOnePlus RealTime PCR System (Applied Biosystems). GAPDH was used as an endogenous control to normalize the samples using the C T method of relative quantification, where C T is the threshold cycle. For immunohistochemical staining for human TSLP, human esophageal biopsies were embedded in paraffin and sectioned. Sections were deparaffinized and stained with a primary human TSLP-specific mAb or an isotype control antibody (validated by J.H. Yearley and R. de Waal Malefyt and commercially produced by Merck Research Laboratories), and positive staining was visualized using the DAB substrate kit (Vector Laboratories).
Flow cytometry.
For mouse studies, esophageal tissues of two or three mice were pooled within each replicate experiment, opened longitudinally, digested in 1 mg mL −1 collagenase/DNase (Roche) for 30 min, and mashed through 70-µm nylon mesh filters. Single-cell suspensions were incubated with Aqua Live/Dead Fixable Dye (Invitrogen) for dead cell exclusion and stained with fluorochromeconjugated mAbs purchased from eBioscience specific for mouse CD3ε 
